Cite this article
Volume | Year
Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.
Open Access Review
Managing the High-Risk Patient: Experience with Fenoldopam, a Selective Dopamine Receptor Agonist, in Prevention of Radiocontrast Nephropathy During Percutaneous Coronary Intervention
1 Cardiac Catheterization Laboratory of the Cardiovascular Institute,Mount Sinai School of Medicine, New York, NY
Rev. Cardiovasc. Med. 2001, 2(S1), 19–25;
Published: 20 January 2001
Acute worsening of renal function due to contrast agents occurs in 15% to 40% of patients with baseline renal insufficiency undergoing percutaneous coronary intervention. Radiocontrast nephropathy is associated with increased morbidity, prolonged hospitalization, and higher in-hospital mortalit y. Our nonrandomized data suggest that in adequately hydrated patients, the dopamine-1 receptor agonist fenoldopam is a useful adjunct during PCI for prevention of RCN, reducing its incidence to less than 5%. This renoprotective effect of fenoldopam was more pronounced in diabetics, with moderate renal failure, in whom no agent has been shown so far to be beneficial.
Radiographic contrast nephropathy
Percutaneous coronary intervention
Chronic renal insufficiency